A Study of JNJ-55308942 in the Treatment of Bipolar Depression

NCT05328297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder

Interventions

DRUG: JNJ-55308942
DRUG: Placebo

Sponsor

Janssen Pharmaceutica N.V., Belgium